What is the Market's View on Intellia Therapeutics Inc (NTLA) Stock's Price and Volume Trends Thursday?

The market has been high on Intellia Therapeutics Inc (NTLA) stock recently. NTLA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Intellia Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NTLA!

See Full NTLA Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With NTLA Stock Today?

Intellia Therapeutics Inc (NTLA) stock is higher by 9.2% while the S&P 500 is lower by -0.1% as of 11:17 AM on Thursday, Mar 2. NTLA has gained $3.75 from the previous closing price of $40.75 on volume of 1,485,401 shares. Over the past year the S&P 500 has fallen -8.33% while NTLA is lower by -44.27%. NTLA lost -$6.16 per share in the over the last 12 months.

More About Intellia Therapeutics Inc

Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. Click Here to get the full Stock Report for Intellia Therapeutics Inc stock.